Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127464 · ClinicalTrials.gov registry record · Phase 1
DCVax Plus Poly ICLC in Healthy Volunteers
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01127464 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 43 participants.
The verdict
NCT01127464, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection. The vaccine is composed of a fusion protein containing a human monoclonal antibody specific for the dendritic cell receptor, DEC-205 (CD205), and the HIV gag p24 protein. The vaccine is designed to target HIV antigens directly to endocytic pathways in dendritic cells (DCs) that allow for efficient processing and presentation of multiple HIV peptides on both MHC class I and II products, which will induce HIV-specific CD8+ and CD4+ T cells. This vaccine candidate must be combined with appropriate immunostimulants (adjuvants) to induce immunity to the antigen. In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.
Interventions
- DRUG Placebo
- DRUG Poly-ICLC
- DRUG DCVax-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127464
The ClinicalTrials.gov registry entry for NCT01127464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01127464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01127464 about?
NCT01127464 is a clinical study titled "DCVax Plus Poly ICLC in Healthy Volunteers". DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection. The vaccine is composed of a fusion protein containing a human monoclonal antibody specific for the dendritic cell receptor, DEC-205 (CD205), and the HIV gag p24 protein...
What is the current status of trial NCT01127464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2010-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01127464?
The interventions under investigation include: Placebo (DRUG), Poly-ICLC (DRUG), DCVax-001 (DRUG).
Who is sponsoring clinical trial NCT01127464?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.